公开(公告)号：US20160002319A1

公开(公告)日：2016-01-07

申请号：US14771337

申请日：2014-02-28

Applicant: THERABIOLI, INC.

Inventor： M. Scott Killian ,  Evelin Szakal ,  Girish N. Vyas

IPC: C07K16/10 ,  G01N33/569 ,  A61K39/21 ,  C12N7/00 ,  C07K16/00 ,  C07K14/005

CPC classification number: C07K16/1063 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/5258 ,  C07K14/005 ,  C07K16/005 ,  C07K2317/10 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/622 ,  C07K2317/76 ,  C12N7/00 ,  C12N2740/16051 ,  C12N2740/16063 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16171 ,  G01N33/56983 ,  G01N33/56988

Abstract: The present invention relates to a method for reducing the occurance and/or severity of viral infections. The method embodies procedures for expanding HIV from the blood of HIV antibody negative donors and deriving a non-infectious virus particle product that is antigenic. The procedures for deriving the antigenic, non-infectious virus particle product are optimally designed to maintain the integrity of the envelope proteins while maximizing the depletion of capsid proteins and RNA. The resulting virus particle product, when introduced into humans or non-human animals, enables the production of antibodies that target the natural envelope macromolecular structure that is required for infectivity. The present invention can be applied to producing virus stocks from the blood of HIV-seronegative donors, for deriving non-infectious virus particles that retain intact envelope proteins, for producing anti-viral antibodies, and for administering anti-virus antibodies to patients.

Abstract translation: 本发明涉及一种减少病毒感染发生和/或严重程度的方法。 该方法体现了从HIV抗体阴性供体的血液中扩展HIV的方法，并得到抗原性的非感染性病毒颗粒产物。 用于衍生抗原非感染性病毒颗粒产物的程序被最佳设计以保持包膜蛋白的完整性，同时最大化衣壳蛋白和RNA的消耗。 所得到的病毒颗粒产物在引入人类或非人类动物中时，能够产生靶向传染性所需的天然包膜大分子结构的抗体。 本发明可以应用于从HIV-血清阴性供体供体的血液中产生病毒颗粒，用于产生保留完整包膜蛋白的非感染性病毒颗粒，产生抗病毒抗体，以及向患者施用抗病毒抗体。